Murali Janakiram

Title: The Innovative Contributions of Murali Janakiram in Immunotherapy

Introduction

Murali Janakiram, an accomplished inventor based in Brooklyn, NY, has made significant strides in the field of immunotherapy. With two patents to his name, he is actively involved in groundbreaking research that addresses cancer treatment. His work exemplifies the intersection of science and innovation, positioning him as a noteworthy figure in the medical field.

Latest Patents

Janakiram's most recent patents include innovative methods using TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies. These patents outline methods for treating HHLA2-bearing tumors through a fusion protein that comprises an IgV-like domain of TMIGD2. The invention also presents related compositions and encoding nucleic acids, offering promising therapeutic avenues for patients battling cancer.

Career Highlights

Murali Janakiram is currently associated with the Albert Einstein College of Medicine, where he contributes to pivotal research aimed at advancing cancer treatment methodologies. His commitment to innovation in the medical field is reflected in his successful patent applications, paving the way for new therapies that can improve patient outcomes.

Collaborations

Throughout his career, Janakiram has collaborated with esteemed colleagues, including Xingxing Zang and Jordan M Chinai. These partnerships highlight the importance of teamwork and collaboration in scientific research, as they work together to advance their understanding and treatment of complex diseases.

Conclusion

Murali Janakiram's work in immunotherapy underscores the vital role of inventors in developing new treatment strategies for cancer. With his innovative patents and collaborative spirit, he continues to contribute to the evolving landscape of medical science, offering hope for improved therapeutic options in the fight against cancer.